FDA nod to first treatment for rare genetic brain disorder

The approval comes after a systematic review of published literature

KIMS Hospitals launches India’s first adaptive deep brain stimulation for Parkinson’s patients

Built on the Percept Platform and enhanced with BrainSense technology, the system can adjust stimulation levels in real time, responding to brain signals without manual intervention

FDA nod to YUVIWEL, first once-weekly treatment for kids with achondroplasia

Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications

IRLAB Therapeutics doses first patient in pivotal apathy trial

The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain

Will Forte joins Teva Pharmaceuticals to shine spotlight on Huntington’s disease

HD causes cognitive, behavioral, and physical challenges, including involuntary movements known as HD chorea, which can disrupt daily life

Brenig Therapeutics launches first-in-human trial of novel neurodegenerative therapy

The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026

Neurizon locks in global trademark protection across key pharma markets

The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions

Mahajan Imaging & Labs launches AI-driven blood test to detect Alzheimer’s early

Over 8.8?million Indians aged 60 and above currently live with dementia,

FDA nod to first-ever treatment for fatal pediatric Menkes disease

Novartis to open Florida radioligand facility

New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US